Clinical Trial Update: A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia [Phase 3]

View source ↗

Summary

ETC-1002, a lipid-lowering agent, completed a confirmatory Phase 3 trial in patients with hyper-LDL cholesterolemia. Results from the completed study were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• ETC-1002 (bempedoic acid)

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Hyper-low-density Lipoprotein (LDL) Cholesterolemia | Phase 3 | Status: COMPLETED | Results posted: 2025-03-13